ASDERA develops the first drug to change the course of Alzheimer's / Parkinson's disesease.

There are currently no drugs with a lasting effect for people with AD or PD. The patented ASDERA approach identified the mechanism under lying "deranged" endocytosis and a drug to "rerange" it. 

The mechanism identified is up-regulation of endocytosis (of APP, a-synuclein) and the proposed drug is a derivative of HP-α-cyclo-dextrin to down-regulates the activity of the PI-cycle, which controls endocytosis.

(click on either of the icons in the lower left corner to download a flyer pdf (top) or a  ppt or pdf deck (bottom) with more details)